Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk by Lewis, Sarah J. et al.
Associations between an Obesity Related Genetic
Variant (FTO rs9939609) and Prostate Cancer Risk
Sarah J. Lewis
1*, Ali Murad
1, Lina Chen
1, George Davey Smith
1,2, Jenny Donovan
1, Tom Palmer
1,2,
Freddie Hamdy
3, David Neal
4, J. Athene Lane
1, Michael Davis
1, Angela Cox
5, Richard M. Martin
1,2
1School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, 2MRC Centre for Causal Analysis in Translational Epidemiology, School of Social
and Community Medicine, University of Bristol, Bristol, United Kingdom, 3Nuffield Department of Surgery, John Radcliffe Hospital, Oxford, United Kingdom, 4Department
of Oncology, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom, 5Institute for Cancer Studies, School of Medicine and Biomedical Sciences,
University of Sheffield, Sheffield, United Kingdom
Abstract
Observational studies suggest that obese men have a lower risk of incident prostate cancer, but an increased risk of
advanced and fatal cancers. These observations could be due to confounding, detection bias, or a biological effect of
obesity. Genetic studies are less susceptible to confounding than observational epidemiology and can suggest how
associations between phenotypes (such as obesity) and diseases arise. To determine whether the associations between
obesity and prostate cancer are causal, we conducted a genetic association study of the relationship between a single
nucleotide polymorphism known to be associated with obesity (FTO rs9939609) and prostate cancer. Data are from a
population-based sample of 1550 screen-detected prostate cancers, 1815 age- and general practice matched controls with
unrestricted prostate specific antigen (PSA) values and 1175 low-PSA controls (PSA ,0.5 ng/ml). The rs9939609 A allele,
which was associated with higher BMI in the sample, was inversely associated with overall (odds ratio (OR) versus all
controls =0.93; 95% confidence interval (CI): 0.85–1.02 p=0.12 per allele) and low-grade (OR=0.90; 0.81–0.99 p=0.03 per
allele) prostate cancer risk, but positively associated with high-grade cancer among cases (OR high- versus low-grade cancer
=1.16; 0.99–1.37 p=0.07 per allele). Although evidence for these effects was weak, they are consistent with observational
data based on BMI phenotypes and suggest that the observed association between obesity and prostate cancer is not due
to confounding. Further research should confirm these findings, extend them to other BMI-related genetic variants and
determine whether they are due to detection bias or obesity-related hormonal changes.
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Introduction
Prostate cancer is a major cause of morbidity and mortality
worldwide [1]. Advancing age, skin colour and a family history of
prostate cancer are known predisposing factors [2], but little is
known about modifiable risk factors for the disease. Knowledge of
such factors may aid in the development of preventative and
treatment strategies. Since obesity has been found to be a risk
factor for many forms of cancer [3], and since it is highly prevalent
among westernized societies, it seems reasonable to investigate
whether it could also be a risk factor for prostate cancer.
Observational studies of obesity and prostate cancer have
produced mixed results. A meta-analysis published in 2006 of 22
prospective cohort studies found that obesity was associated with a
small increase in prostate cancer risk [4]. However, when a
stratified analysis was carried-out, the authors found that the
increase was limited to advanced rather than localised disease [4].
Since this meta-analysis, several studies have been published which
indicate that obesity is associated with an increased risk of
advanced or fatal prostate cancer, but with a decreased risk of
localised disease [5–9].
There are several potential explanations for these findings. They
may have arisen as a result of confounding by factors such as
diabetes mellitus. Obesity strongly predisposes to type 2 diabetes
mellitus (T2DM) and epidemiological studies (including our own
[10]) have consistently reported an inverse association between
T2DM and prostate cancer (meta-analysis pooled relative risk,
RR=0.84, 95% CI: 0.76–0.93) [11].
A further explanation could be that obesity makes prostate
cancer identification more difficult, thus predisposing obese men
to present later with more severe disease, but reducing the
identification of low-grade, low volume disease (detection bias,
generating positive association with advanced cancer but inverse
associations with localised disease). This possibility has been
suggested because digital rectal examination is technically more
difficult in obese patients [9], biopsies are more likely to lead to
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logical studies have found that prostate specific antigen (PSA)
concentrations are lower in obese than in non-obese men [12–14],
possibly due to greater plasma volume in obesity resulting in
haemodilution and therefore lower relative concentrations of PSA
[15]. However, the recent Prostate Cancer Prevention Trial
reported that differences in cancer grade and stage were
maintained even amongst a cohort of men who all underwent
prostate biopsy [5], suggesting that detection bias due to lower
PSA levels among obese individuals cannot account for all of the
observed effects. In addition, obesity was positively associated with
clinical progression in men with prostate cancer (i.e. who all
underwent prostate biopsy), independent of cancer grade, stage
and primary treatment [16].
Whilst detection of prostate cancer may be more difficult
amongst obese men, the treatment received by those obese
patients who do develop prostate cancer may be less effective than
that received by non-obese patients, for example, as a result of
technical difficulties during surgery [17] or difficulty in targeting
radiotherapy [18].
It is also possible that hormonal changes associated with obesity
increase the proliferative potential of prostate cancer. In vitro and
epidemiological studies have demonstrated that steroid hormones,
leptin and insulin-like growth factor-1 (IGF-1), all of which are
raised among obese individuals, increase prostatic tumour cell
proliferation [19,20].
In summary, whilst epidemiological studies have identified
differences in prostate cancer risk between obese and non-obese
men, the possibility of confounding and bias means that a causal
effect of obesity on prostate cancer risk has not yet been
conclusively demonstrated. Genetic studies are less susceptible to
confounding than observational epidemiology [21] and may offer
a complimentary study design [22]. The existence of genetic
variations that alter risk of developing both obesity and prostate
cancer could constitute evidence in favour of a causal link between
the two diseases.
A single nucleotide polymorphism (SNP), known to be
associated with obesity (FTO rs9939609), has been robustly
associated with increased body mass index (BMI) and obesity in
multiple study populations [23–26]. It has been suggested that this
effect is mediated through a reduction in satiety [27] and
consequent increased food consumption [28]. The rs9939609
SNP may, therefore, present an un-confounded exposure with
which to investigate the causal association between obesity and
prostate cancer.
We hypothesised that the AA genotype of rs9939609, which is
associated with an increase in BMI, would protect against non-
aggressive prostate tumours whilst increasing the risk of aggressive
prostate tumours. To test this hypothesis, we present data from a
large, case-control study nested within the population-based phase
of the ProtecT (Prostate testing for cancer and Treatment study)
trial.
Materials and Methods
Study participants
Participants in this study were selected from the Prostate testing
for cancer and Treatment study (ProtecT), which is a randomized
controlled trial taking place in nine regions of the UK with the aim
of evaluating the efficacy, cost effectiveness, and acceptability of
treatments for localized prostate cancer. All men aged 50–69 years
from approximately 300 general practices and without known
prostate cancer, were invited to attend a nurse-led prostate check
clinic and have a PSA test. The invitations were sent between 2001
and 2008 and over 89,000 men attended the prostate check clinic.
Participants with a single raised PSA level over 3.0 ng/ml were
invited to attend the centre’s urology department for digital rectal
examination (DRE), repeat PSA test, and transrectal ultrasound
(TRUS) guided biopsy (10 cores), or referred to a urologist if the
PSA level was over 20 ng/ml, to confirm prostate cancer status.
The age of the participants when they attended the prostate check
clinic, PSA level, height, weight, smoking status, physical exercise
and self-reported ethnicity and diabetes were collected either by
questionnaire or by nurse interview. In this study, our case
population consisted of all men with prostate cancer identified at
prostate check clinics conducted before the end of November 2006
who gave consent for genotyping.
Prostate cancer stage was defined according to the 2002 TNM
staging system [29]. Patients with cancer stage between T0-T2
were defined as having localized stage cancer, while individuals
with a cancer stage greater than T2 were defined as advanced
stage cases. Histological cancer grade was defined by Gleason
score using grade 7 as the cut-off (lower grade: ,7; higher grade:
$7). We found little overlap between more aggressive prostate
cancer cases defined by these two methods. Only 19.4% of
patients with Gleason score $7 have cancer stage $T2, whereas
72.2% of patients at stage $T2 have Gleason score $7.
Two non-overlapping groups of controls were randomly
selected from the pool of men who attended the prostate check
clinics and did not have prostate cancer diagnosed. One control
group included only participants without a diagnosis of prostate
cancer and with a PSA concentration ,0.5 ng/ml (‘low PSA/
super-normal controls’). The other group included only partici-
pants without a diagnosis of prostate cancer and placed no
restriction on PSA concentration (‘unrestricted controls’). Unre-
stricted controls were stratum matched to cases by age (5-year
bands) and the primary care centre (general practice) from which
men were recruited; low PSA controls were matched to cases
where possible, but if a matched low PSA control was not
available, an unmatched low PSA control was selected. Multi-
centre Research Ethics Committee approval was obtained from
Trent MREC, and written consent for performing anonymized
genotyping on stored blood was obtained from individual
participants. Detailed descriptions of the ProtecT study and the
protocol for nested case-control selection are published elsewhere
[30–32].
DNA extraction and genotyping
DNA extraction was performed by Tepnel (http://www.tepnel.
com). The FTO rs9939609 variant was genotyped in ProtecT
participants as part of a genetic association study examining the
effect of 70 diet/nutrition relevant SNPs on prostate cancer risk
and was undertaken by KBioscience Ltd (www.kbioscience.co.uk),
who use their own form of competitive allele-specific PCR
(KASPar) and Taqman
TM, for SNP analysis. Samples with more
than 10% genotype failure (7 SNPs) were defined as having poor
DNA quality (2.6%) and dropped from further analysis. Geno-
typing was repeated in 10% of the study samples (with
independent assessment) and for 99.98% of those samples there
was exact agreement between the two.
Statistical analysis
A Pearson x
2-test was performed amongst controls to ensure
that genotype distribution satisfied Hardy-Weinberg equilibrium.
We tested for differences in demographic and lifestyle character-
istics between cases and controls and between low PSA and other
controls. We also tested for differences in these characteristics
between genotypes. We used Student’s t-test for quantitative
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intensity scores and weekly drinking and x
2 tests for ordered
categorical variables, such as smoking status (current smoker, ever
smoker and non-smoker) and social class (professional, intermedi-
ate and manual). Associations of rs9939609 with all prostate
cancers and prostate cancer stage or grade were calculated using
unconditional logistic regression models adjusted for exact age at
prostate check clinic and study centre (9-level variable).
Instrumental variable (IV) estimation of the effect of BMI on
prostate cancer was performed by dividing the genotype-outcome
log odds ratios by the genotype-BMI association from the controls,
known as the Wald type estimator or ratio of coefficients approach
[33,34]. This estimate was exponentiated to give a causal odds
ratio per unit change in BMI. The standard error of the IV
estimate on the log scale was calculated using a Taylor series of the
ratio of two means [35] Statistical analyses were carried out in
Statastatistical software (version 10; Stata Corporation, College
Station, TX). P-values are two-sided.
Results
DNA samples from 4664 participants were submitted for
genotyping. We excluded 91 individuals who reported being of
ethnicities other than white European in an attempt to avoid
population stratification in our analysis. The distributions of co-
variables in the remaining population are outlined in Table 1.
Cases were more likely to have a family history of cancer than
controls and more likely to be non-smokers, but did not differ in
relation to BMI, waist-hip ratio, exercise intensity score, alcohol
intake, or social class. Low PSA controls were younger, had a
higher BMI and drank more alcohol than the ‘unrestricted’
controls.
Genotyping was successfully carried out for 1550 of 1566
(99.0%) cases, 1815 out of 1824 (99.5%) controls, and 1175 of
1183 (99.3%) controls. Genotypes conformed to Hardy-Weinberg
equilibrium in all 3 groups (cases p=0.91, ‘unrestricted’ controls
p=0.36, low PSA controls p=0.14). Four hundred and forty nine
out of 1545 men in whom histological grade was confirmed were
defined as having high-grade cancer, whereas only 196 out of 1546
cases were defined as having advanced-stage cancer.
Table 2 shows the association between the FTO rs9939606
genotype and the baseline characteristics of the ‘unrestricted’
control population. There were no differences in the distribution
of these variables by genotype; they cannot, therefore, confound
the association between genotype and disease risk.
Table 3 shows the association between genotype and mean
BMI among cases, ‘unrestricted’ controls and ‘low-PSA’ controls.
The difference between AA and TT genotypes was similar among
the 3 groups with an overall difference of 0.56 kg/m
2 (p=0.007).
We also assessed the association between genotype and log PSA
level among the cases and normal (‘unrestricted’) controls
(Table 4), but not amongst the low PSA controls (because these
were selected to have extremely low PSA levels (,0.5 ng/ml)
which is around the limit of detection and it is therefore likely that
the ability to detect differences in PSA levels by genotype will be
low in this group). We found no strong statistical evidence of any
differences in log PSA level by genotype (mean log PSA differences
comparing AA versus TT were 20.07 and 20.06 amongst cases
and controls, respectively).
Table 5 shows the results of our analyses of associations
between genotype and prostate cancer risk. Those with the A allele
had a lower odds of all- or low-grade cancers, compared to those
with the TT genotype (p-values for per allele effects were between
0.03 and 0.18). The results for all cases versus all controls
Table 1. Characteristics of the study population.
Matched
‘unrestricted’
controls
Prostate cancer
cases p-value Low PSA controls p-value
No. of participants 1824 1566 — 1183 —
Family history
Yes 95 (5.2) 116 (7.4) 0.008 46 (3.9) 0.10
No 1730 (94.8) 1450 (92.6) 1137 (96.1)
Age in years (mean6sd), year 62.765.0 62.565.1 0.36 60.865.4 ,0.0001
PSA (mean6sd)*, ng/ml 1.361.4 9.3626.1 ,0.0001 0.3660.1 N/A
BMI (mean6sd), kg/m
2 26.863.7 26.763.6 0.41 27.564.1 0.0001
WHR (mean6sd), unit 0.9360.002 0.9360.002 0.95 0.9360.002 0.99
Exercise intensity scores (mean6sd)*, unit 22.6633.6 23.2634.9 0.07 22.8633.6 0.75
Weekly drinking (mean6sd)*, unit 19.0617.8 17.7616.7 0.09 21.7619.8 0.009
Social class (n,%)
Professional 722 (44.0) 721 (46.7) 0.26 398 (47.9) 0.18
Intermediate 279 (15.9) 245 (15.8) 122 (14.7)
Manual 703 (40.1) 579 (37.5) 311 (37.4)
Smoking (n, %)
Non-smoker 405 (32.6) 430 (37.3) 0.045 277 (32.7) 0.75
Ever smoker 661 (53.3) 561 (48.6) 441 (52.1)
Current Smoker 175 (14.1) 163 (14.1) 129 (15.2)
‘Unrestricted’ controls are the baseline group for comparison,
*p-values are calculated based on log transformed data.
doi:10.1371/journal.pone.0013485.t001
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allele (95% CI=22% to 15%). There was evidence of a 10%
reduction (1% to 19%) in risk of low grade prostate cancer per A
allele (p=0.03). There was no association with having high grade
or advanced stage cancer per se, but among cases the results for
high-grade versus low-grade cancer suggested that risk of high
grade disease was increased by 16% per A allele (95% CI-1% to
37%, p=0.07). However, p-values were not sufficiently small to
provide strong evidence against the null hypothesis. Adjustment by
whether men had diabetes or not (self-report) made no difference
to the results (not shown).
Instrumental variable estimates (Table 6) gave an OR of 0.77
(95% CI 0.52, 1.15) for prostate cancer per unit increase in BMI
(using the per allele estimates for genotype) and an OR of 1.35
(95% CI 0.90, 2.03) for high-grade versus low-grade cancer per
unit increase in BMI.
Discussion
To our knowledge, this is the first study to look for a possible
association between a SNP predisposing to obesity and prostate
cancer. Our large, population-based, nested case-control study has
found weak evidence that the rs9939609 A allele, which has
previously been associated with obesity and is associated with
raised BMI amongst our study population, protects against
prostate cancer incidence, and stronger evidence that the same
genotype protects against low-grade prostate cancer. This
supports findings from epidemiological studies including our own
[36], which have noted that obesity protects against localised
prostate cancer. Our study found some evidence that rs9939609 A
allele increases the risk of high-grade versus low-grade cancer
among cases but FTO genotype was not associated with the
presence of high grade or advanced stage disease per se (i.e. in
Table 2. Characteristics of the matched ‘unrestricted’ control population by FTO rs9939609 genotype.
TT TA p-value AA p-value
Total No. of participants 676 848 — 291 —
Family history
Yes 39 (5.8) 42 (5.0) 0.48 14 (4.8) 0.55
No 637 (94.2) 806 (95.1) 227 (95.2)
Age in years (mean6sd), year 63.065.1 62.465.0 0.03 62.965.0 0.69
PSA (mean6sd)*, ng/ml 1.361.3 1.361.5 0.89 1.261.3 0.30
BMI (mean6sd), kg/m
2 26.563.6 27.063.7 0.07 26.964.0 0.22
WHR (mean6sd), unit 0.9360.06 0.9460.06 0.17 0.9460.06 0.31
Exercise intensity scores (mean6sd)*, unit 23.5633.8 20.5628.8 0.43 26.7640.1 0.21
Weekly drinking (mean6sd)*, unit 18.5616.7 20.5619.3 0.23 15.4614.4 0.36
Social class (n,%)
Professional 276 (42.8) 369 (45.2) 0.65 123 (43.5) 0.97
Intermediate 106 (16.4) 127 (15.6) 45 (15.9)
Manual 263 (40.8) 320 (39.2) 115 (40.6)
Smoking (n, %)
Non-smoker 159 (32.9) 179 (32.8) 0.71 65 (31.7) 0.80
Ever smoker 252 (52.0) 294 (53.9) 112 (54.6)
Current Smoker 73 (15.1) 73 (13.3) 28 (13.7)
The TT genotype is the baseline category for comparison,
*p-values are calculated based on log transformed data.
doi:10.1371/journal.pone.0013485.t002
Table 3. Association between BMI and FTO genotype (adjusted by age and centre).
TT TA
Mean difference, 95%
CI (TA minus TT) p AA
Mean difference, 95%
CI (AA minus TT) p per allele effect p
Low PSA Controls 27.364.0 27.463.9 0.05 (20.57, 0.68) 0.86 28.164.7 0.77 (20.06, 1.61) 0.07 0.32 (20.08, 0.73) 0.12
Matched
‘unrestricted’
controls
26.563.6 27.063.7 0.44 (20.04, 0.91) 0.07 26.964.0 0.39 (20.24, 1.03) 0.22 0.24 (20.06, 0.55) 0.11
Cancer Cases 26.563.5 26.663.6 0.08 (20.39, 0.55) 0.74 27.163.6 0.49 (20.16, 1.15) 0.14 0.21(20.10, 0.52) 0.19
All controls 26.863.8 27.163.8 0.29 (20.9, 0.67) 0.13 27.464.3 0.57 (0.06, 1.07) 0.03 0.28 (0.04, 0.53) 0.02
Low grade cancers 26.363.2 26.763.7 0.39 (20.16,0.94) 0.16 27.463.6 1.04 (0.25, 1.83) 0.01 0.49 (0.12, 0.86) 0.01
CI = confidence interval.
doi:10.1371/journal.pone.0013485.t003
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findings, we did not find an association between BMI and high
grade or advanced stage prostate cancer or even with prostate
cancer risk overall in our observational analysis [36].
Whilst our effect sizes by genotype were relatively modest, it is
important to note that the effect of genotype on BMI was also
modest with a per allele difference of 0.28 kg/m
2. The
instrumental variable analysis suggests that prostate cancer risk is
reduced by 23% per BMI unit, which would be quite substantial,
although confidence intervals around this effect are wide reflecting
both the uncertainty in the genotype-BMI association and the
uncertainty in the genotype-prostate cancer association.
In our sub group of the ProtecT study (for which DNA was
available) we did not find any difference in mean BMI between
cases and controls, but a morecomprehensive analysis not restricted
to those with DNA found an inverse association of increasing BMI
with localised cancer (unpublished work) suggesting that power may
have been an issue in our study. Approximately one third of men
included in our genotype analysis did not report their BMI and so
could not be included in the BMI - cancer association analysis
presented in Table 1. If there were a tendency for overweight men
to not report their BMI, then this would bias our observational
results, but not our genotype results (as very few eligible men were
excluded from the genotype analysis) towards the null.
It is important to note that unlike other studies which found that
high grade or advanced stage cancer were more prevalent among
men with a higher BMI, we found BMI to be associated with
prostate cancer grade among cases, but we found no difference in
genotype distributions (and therefore BMI) between high grade
cancers and controls. Also, although we measured more aggressive
prostate cancer using both Gleason grade and TNM staging, the
strongest effects in our study were found using a classification of
Gleason grade. We observed similar effects in an earlier analysis of
vitamin D and prostate cancer progression [we reported and
discussed this in detail in ref 36]. In a study comparing the
predictive ability of the two systems for classifying prostate cancer,
Gleason score has been reported to have higher predictive
accuracy for biochemical recurrence compared with TNM staging
[37]. Interestingly, in the meta-analysis of BMI and prostate
cancer by MacInnes and English [4], the study which showed the
largest effect of BMI on increased risk of more aggressive cancer
was that which used Gleason grading; all other studies used TNM
staging and their results were all compatible with no increased risk.
Alternatively the fact that we and others found no evidence of an
increase risk for advanced stage among men with prostate cancer
could simply be due to low power to detect an effect. In this study
there were only 196 men in the advanced stage group, as opposed
to 449 in the high grade group. Confidence intervals for the effect
estimates for both high grade and advanced stage were
overlapping and compatible with there being an increased risk
for advanced stage as well as high grade cancer. We had around
57% power to detect a 10% increase or decrease in prostate cancer
risk per FTO allele, but only around 14% power to detect a similar
effect with advanced stage cancer. Future studies would need to be
of the order of 2700 cases (or advanced cases, depending on the
question) to have 80% power to detect an effect of this order with
FTO genotype.
Our study has several advantages over traditional epidemiolog-
ical studies. Genetic studies of disease risk are less susceptible to
confounding and reverse causation and we can therefore be
reasonably confident that the protective effect of the rs9939609
genotype is not due to these factors. In this study adjustment by
whether men reported having diabetes or not made no difference to
our results, suggesting that diabetes is not a confounder in the
association between FTO genotype and prostate cancer risk. This is
in line with Gong et al [5] who found in their observational study
that the association between obesity and prostate cancer risk was
independent of diabetes. Furthermore, whilst we cannot ruleout the
possibility that our results are due to detection bias, the lack of an
effect of rs9939609 on PSA concentration (Table 4) suggests that
Table 4. Association between log PSA and FTO genotype.
TT TA Mean difference p AA Mean difference p per allele effect p
Matched Controls 20.0960.85 20.1060.83 20.006 (20.09, 0.08) 0.89 20.1560.85 20.06 (20.18, 0.05) 0.30 20.03 (20.08, 0.03) 0.36
Cancer Cases 1.8560.68 1.8160.72 20.03 (20.11,0.05) 0.43 1.7860.62 20.07 (20.17, 0.03) 0.19 20.03 (20.08, 0.02) 0.20
doi:10.1371/journal.pone.0013485.t004
Table 5. Association between FTO genotype and prostate cancer outcomes adjusted by age and study centre.
TA vs TT AA vs TT per allele effect
Odds Ratio (95%CI) p Odds Ratio (95%CI) p Odds Ratio (95%CI) p
Cancer cases (n=1550) vs matched controls (n=1815) 0.96 (0.83–1.12) 0.62 0.86 (0.70–1.06) 0.16 0.94 (0.85–1.03) 0.18
Cancer cases (n=1550) vs low PSA controls (n=1175) 0.99 (0.83–1.17) 0.87 0.82 (0.65–1.03) 0.09 0.92 (0.82–1.03) 0.14
Cancer cases (n=1550) vs all controls (n=2990) 0.98 (0.85–1.12) 0.73 0.84 (0.70–1.02) 0.08 0.93 (0.85–1.02) 0.12
Low grade cancers (n=1096) vs all controls (n=2990) 0.94 (0.80–1.09) 0.38 0.78 (0.63–0.97) 0.02 0.90 (0.81–0.99) 0.03
Localized stage (n=1350) vs all controls (n=2990) 0.95 (0.83–1.10) 0.50 0.87 (0.71–1.05) 0.15 0.94 (0.85–1.03) 0.16
High grade (n=449) vs low grade (n=1096) 1.20 (0.94–1.54) 0.14 1.33 (0.95–1.88) 0.10 1.16 (0.99–1.37) 0.07
Advanced stage (n=196) vs localized stage (n=1350) 1.27 (0.91–1.77) 0.16 0.79 (0.47–1.34) 0.38 0.99 (0.79–1.23) 0.90
High grade (n=449) vs all controls (n=2990) 1.09 (0.87–1.36) 0.45 1.01 (0.75–1.37) 0.94 1.02 (0.89–1.18) 0.78
Advanced stage (n=196) vs all controls (n=2990) 1.14 (0.83–1.57) 0.40 0.68 (0.41–1.12) 0.13 0.91 (0.73–1.12) 0.36
doi:10.1371/journal.pone.0013485.t005
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p-values and apply a correction factor based on the mean difference
in log PSA levels between controls with the AA and those with the
TT genotype, we find that under-detection due to a lower PSA level
among AA individuals cannot explain our results. The mean
difference in log PSA levels between AA and TT genotypes was
20.06units; this equates to a geometric mean difference of 0.94, i.e.
a 6% difference on a log scale. If we were to lower our PSA cut-off
by 6% among AA individuals we would have biopsied a further 3
individuals. Since the chance of detecting prostate cancer among
biopsied individuals in our study was 25%, we would expect 0.75
cases to have been missed due to lower PSA levels among AA
individuals. This would not affect the results of our analysis of
genotype and cancer risk. In addition, because our prostate cancer
cases came from a population based cohort study our results are
unlikely to have arisen by survivor bias. However, whilst PSA
detection bias is unlikely to explain our results, it is possible that
detection bias due to biopsy could have occurred. It has been
suggested that biopsies among obese men are more likely to lead to
false negatives due to enlarged tissue [9]. In future studies it will be
important to clarify the degree to which detection bias is responsible
for associations between BMI and prostate cancer and whether
there is another causal mechanism which is responsible for the
observed association. These issues could be addressed by more
thorough examination and a greater number of biopsies among
obese men and also by investigating the extent to which other
pathways such as hormonal pathways could explain the association.
Mendelian randomization offers evidence that is complimentary
to that provided by conventional observational epidemiology, and
can avoid confounding by lifestyle factors and bias due to reverse
causation [21]. However it is important to note that there are
limitations to this approach. The biological consequences of
variation at the FTO locus and the mechanism of the observed
association of this with fat mass are still unclear. Several studies
exist which point to a role for this locus in energy regulation and
hypothalamically regulated patterns of appetite [27–28,38–42].
However, the possibility of pleiotrophy in the association between
FTO genotype and prostate cancer risk cannot be completely
ruled out. In this case, utilizing multiple instruments that is, several
independent genetic variants that are associated with BMI could
help strengthen the causal inference, as pleiotropic effects are
unlikely to influence the effects of each instrument in the same
manner [22]. In addition it is possible to generate multiple
combinations of genetic variants that are independent of each
other to generate many independent variable estimates as
described in [43]. Future studies using multiple genetic instru-
ments could also use combinations of alleles, as allele scores, to
increase power and strengthen the IV estimation [44].
In conclusion, our data provides some evidence (albeit weak)
that the A allele of rs9939609 may protect against prostate cancer
risk or reduce the likelihood of this disease being detected (in
particular low-grade cancer), but may increase the likelihood of
cases having high grade as opposed to low grade prostate cancer at
diagnosis. These observations support the findings from epidemi-
ological studies that obesity protects against localised prostate
cancer but increases the risk of advanced cancer. Further studies of
this SNP and investigations of other obesity associated polymor-
phisms are required to provide clarity in this area.
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